WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017195224) RHO GTPASE ACTIVATING BACTERIAL TOXINS FOR USE IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM BY MUCOSAL ADMINISTRATION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/195224    International Application No.:    PCT/IT2016/000120
Publication Date: 16.11.2017 International Filing Date: 09.05.2016
IPC:
A61K 38/16 (2006.01), A61P 25/00 (2006.01)
Applicants: ISTITUTO SUPERIORE DI SANITA' [IT/IT]; Viale Regina Elena, 299 00161 Roma (RM) (IT)
Inventors: DIANA, Giovanni; (IT)
Agent: GITTO, Serena; Barzano' & Zanardo Roma S.p.A. Via Piemonte, 26 00187 Roma (IT)
Priority Data:
Title (EN) RHO GTPASE ACTIVATING BACTERIAL TOXINS FOR USE IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM BY MUCOSAL ADMINISTRATION
(FR) TOXINES BACTÉRIENNES ACTIVANT LA RHO GTPASE POUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL PAR ADMINISTRATION PAR VOIE MUQUEUSE
Abstract: front page image
(EN)The present invention concerns Rho GTPase activating bacterial toxins for use in treatment of cognitive impairment and neurodegenerative diseases such as Parkinson's disease by topical ocular, nasal or enteral administration, wherein said Rho GTPase activating protein toxins are chosen from the group consisting of Cytotoxic Necrotizing Factor 1 (CNF1 ) and Cytotoxic Necrotizing Factor 2 (CNF2).
(FR)La présente invention concerne des toxines bactériennes activant la Rho GTPase pour utilisation dans le traitement d'un trouble cognitif et de maladies neurodégénératives telles que la maladie de Parkinson par administration topique oculaire, nasale ou entérale, lesdites toxines protéiques activant la Rho GTPase étant choisies dans le groupe constitué du facteur de nécrose cytotoxique 1 (CNF1) et du facteur de nécrose cytotoxique 2 (CNF2).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)